The US Supreme Court’s ruling in the battle over access to the abortion pill mifepristone could determine whether the tighter pre-2016 restrictions on its use will go back into effect. But more broadly, the case could impact the US Food and Drug Administration’s scientific decisions about other drugs.
Supreme Court Could Curtail Mifepristone Access, Lay Out ‘Road Map’ To Challenge FDA Approvals
Court decision on whether an anti-abortion group has standing to challenge FDA actions could dispose of case or open door to similar suits. Ruling will determine if pre-2016 REMS restrictions are reinstated.
